Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

How do males recover from eating disorders? An interview study.

Pettersen G, Wallin K, Björk T.

BMJ Open. 2016 Aug 11;6(8):e010760. doi: 10.1136/bmjopen-2015-010760.

2.

Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.

Merseburger AS, Björk T, Whitehouse J, Meani D.

J Comp Eff Res. 2015 Sep;4(5):447-53. doi: 10.2217/cer.14.82. Epub 2014 Dec 18.

3.

Eating disorders and anabolic androgenic steroids in males--similarities and differences in self-image and psychiatric symptoms.

Björk T, Skårberg K, Engström I.

Subst Abuse Treat Prev Policy. 2013 Aug 19;8:30. doi: 10.1186/1747-597X-8-30.

4.

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H.

BMJ. 2013 Apr 15;346:f2023. doi: 10.1136/bmj.f2023.

5.

Male experiences of life after recovery from an eating disorder.

Björk T, Wallin K, Pettersen G.

Eat Disord. 2012;20(5):460-8. doi: 10.1080/10640266.2012.715529.

PMID:
22985242
6.

Laterality, hand control and scholastic performance: a British birth cohort study.

Björk T, Brus O, Osika W, Montgomery S.

BMJ Open. 2012 Mar 22;2(2):e000314. doi: 10.1136/bmjopen-2011-000314. Print 2012.

7.

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM.

Eur Urol. 2012 Jul;62(1):78-84. doi: 10.1016/j.eururo.2012.01.037. Epub 2012 Jan 27.

8.

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.

Christensson A, Bruun L, Björk T, Cronin AM, Vickers AJ, Savage CJ, Lilja H.

BJU Int. 2011 Jun;107(11):1769-74. doi: 10.1111/j.1464-410X.2010.09761.x. Epub 2010 Oct 18.

9.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H.

BMJ. 2010 Sep 14;341:c4521. doi: 10.1136/bmj.c4521.

10.

The impact of different outcome measures on estimates of remission in a 3-year follow-up of eating disorders.

Björk T, Clinton D, Norring C.

Eur Eat Disord Rev. 2011 Jan-Feb;19(1):2-11. doi: 10.1002/erv.1031.

PMID:
20597067
11.

What happened to the ones who dropped out? Outcome in eating disorder patients who complete or prematurely terminate treatment.

Björk T, Björck C, Clinton D, Sohlberg S, Norring C.

Eur Eat Disord Rev. 2009 Mar;17(2):109-19. doi: 10.1002/erv.911.

PMID:
19142975
12.

The patient's perception of having recovered from an eating disorder.

Björk T, Ahlström G.

Health Care Women Int. 2008 Sep;29(8):926-44. doi: 10.1080/07399330802269543.

PMID:
18726799
13.

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H.

J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490.

PMID:
18281654
14.

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.

Ulmert D, Cronin AM, Björk T, O'Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H.

BMC Med. 2008 Feb 15;6:6. doi: 10.1186/1741-7015-6-6.

15.

[Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].

Bratt O, Björk T.

Lakartidningen. 2007 Nov 14-20;104(46):3460-4. Review. Swedish. No abstract available.

PMID:
18072615
16.

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

Vickers AJ, Ulmert D, Serio AM, Björk T, Scardino PT, Eastham JA, Berglund G, Lilja H.

Int J Cancer. 2007 Nov 15;121(10):2212-7.

17.

Self-image and treatment drop-out in eating disorders.

Björck C, Björk T, Clinton D, Sohlberg S, Norring C.

Psychol Psychother. 2008 Mar;81(Pt 1):95-104.

PMID:
17631699
18.

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G.

J Clin Oncol. 2007 Feb 1;25(4):431-6.

PMID:
17264339
19.

Reasons for non-participation in follow-up research on eating disorders.

Björk T, Clinton D, Norring C.

Eat Weight Disord. 2006 Sep;11(3):147-53.

PMID:
17075242
20.

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.

Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T.

BJU Int. 2006 Sep;98(3):563-72. Epub 2006 Jun 8. Erratum in: BJU Int. 2006 Sep;98(3):572.

21.

Mortality among mentally disordered offenders: a community based follow-up study.

Björk T, Lindqvist P.

Crim Behav Ment Health. 2005;15(2):93-6.

PMID:
16470503
22.

Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.

Bjartell A, Johansson R, Björk T, Gadaleanu V, Lundwall A, Lilja H, Kjeldsen L, Udby L.

Prostate. 2006 May 1;66(6):591-603.

PMID:
16388501
23.

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.

Ulmert D, Becker C, Nilsson JA, Piironen T, Björk T, Hugosson J, Berglund G, Lilja H.

Clin Chem. 2006 Feb;52(2):235-9. Epub 2005 Dec 29.

PMID:
16384894
24.

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.

Bruun L, Ekberg H, Bjørk T, Lilja H, Høglund P, Christensson A.

J Urol. 2004 Apr;171(4):1432-5.

PMID:
15017191
25.

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J.

Clin Cancer Res. 2003 Jun;9(6):2040-8.

26.

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.

Bruun L, Björk T, Lilja H, Becker C, Gustafsson O, Christensson A.

Nephrol Dial Transplant. 2003 Mar;18(3):598-603.

PMID:
12584285
27.

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J.

J Clin Oncol. 2002 Nov 1;20(21):4292-302.

PMID:
12409327
28.

[Length of stay within forensic psychiatry--reality report].

Lindqvist P, Björk T.

Lakartidningen. 2002 Jun 20;99(25):2878-9. Swedish. No abstract available.

PMID:
12143147
30.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.

J Urol. 2000 Jan;163(1):311-6.

PMID:
10604382
31.
32.

Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.

Lilja H, Haese A, Björk T, Friedrich MG, Piironen T, Pettersson K, Huland E, Huland H.

J Urol. 1999 Dec;162(6):2029-34; discussion 2034-5.

PMID:
10569562
33.

Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum.

Björk T, Ljungberg B, Piironen T, Abrahamsson PA, Pettersson K, Cockett AT, Lilja H.

Urology. 1998 Jan;51(1):57-62.

PMID:
9457289
34.

Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.

Björk T, Piironen T, Pettersson K, Lövgren T, Stenman UH, Oesterling JE, Abrahamsson PA, Lilja H.

Urology. 1996 Dec;48(6):882-8.

PMID:
8973671
35.

Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues.

Sundkvist GM, Björk T, Kjellström H, Lilja B.

Scand J Urol Nephrol. 1996 Feb;30(1):29-32.

PMID:
8727862
36.

Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.

Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T.

Clin Chem. 1995 Aug;41(8 Pt 1):1115-20.

37.

Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.

Björk T, Bjartell A, Abrahamsson PA, Hulkko S, di Sant'Agnese A, Lilja H.

Urology. 1994 Apr;43(4):427-34.

PMID:
7512295
38.

Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium.

Bjartell A, Björk T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H.

Urology. 1993 Nov;42(5):502-10.

PMID:
7694414
39.

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.

Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H.

J Urol. 1993 Jul;150(1):100-5.

PMID:
7685416
40.

Lipoxin formation in human nasal polyps and bronchial tissue.

Edenius C, Kumlin M, Björk T, Anggård A, Lindgren JA.

FEBS Lett. 1990 Oct 15;272(1-2):25-8.

41.

Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women.

Abrahamsson PA, Andersson C, Björk T, Fernlund P, Lilja H, Murne A, Weiber H.

Clin Chem. 1989 Jul;35(7):1497-503.

42.

Use of ciprofloxacin in patients undergoing transurethral prostatic surgery.

Hellsten S, Forsgren A, Björk T, Grabe M.

Scand J Infect Dis Suppl. 1989;60:104-7.

PMID:
2756349
43.

Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery.

Grabe M, Forsgren A, Björk T, Hellsten S.

Eur J Clin Microbiol. 1987 Feb;6(1):11-7.

PMID:
3569248
44.

Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection.

Grabe M, Forsgren A, Björk T.

Eur J Clin Microbiol. 1986 Apr;5(2):211-2. No abstract available.

PMID:
2424755
45.

[Tentative use of climatotherapy in the Canary Islands].

BJORK T.

Sven Lakartidn. 1952 Apr 10;49(15):987-9. Undetermined Language. No abstract available.

PMID:
14958634

Supplemental Content

Support Center